检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《中药药理与临床》2016年第4期16-19,共4页Pharmacology and Clinics of Chinese Materia Medica
基 金:宁夏科技支撑计划项目(抗哮喘药物甘草次酸的研发及机制研究;2015)
摘 要:目的:观察甘草次酸对哮喘大鼠气道炎症、气道重塑及肺组织Casepase-3、Bax、Bcl-2表达的影响,探讨其抗哮喘机制。方法:将60只雄性大鼠随机分为正常对照组、哮喘模型组、地塞米松组及甘草次酸(200、100、50mg/kg)剂量组。以卵清蛋白加氢氧化铝致敏复制大鼠哮喘动物模型,病理观察甘草次酸对哮喘大鼠肺组织气道炎症浸润和气道重塑的影响;采用RT-PCR和Western-blot法检测哮喘大鼠肺组织Casepase-3、Bax及Bcl-2 mRNA和蛋白表达。结果:与哮喘模型组比较,甘草次酸200mg/kg可减少哮喘大鼠肺组织炎症浸润,改善或逆转气道重塑;甘草次酸200、100 mg/kg可上调哮喘大鼠肺组织Bax、Caspase-3 mRNA和蛋白表达水平,下调Bcl-2mRNA和蛋白表达水平。结论:甘草次酸对哮喘大鼠气道炎症及气道重塑有较好的改善作用,其机制可能与上调促凋亡因子Bax、Caspase-3和下调抗凋亡因子Bcl-2有关。Objective: To observe the effects of glycyrrhetinic acid (GA) on airway remodeling, Caspase-3, Bax and Bcl-2 of lung tissue in bron- chial asthma rats, and investigate its anti-asthma mechanism. Methods: Sixty male rats were randomly divided into 6 groups: normal con- trol, asthma model, dexamethasone and GA 200, 100, 50 mg/kg group. The bronchial asthma rat's model was induced by intraperitoneal in- jected and inhaled with ovalbumin and aluminum hydroxide solution, Using the HE staining to observe the effects of GA on airway inflamma- tion and remodeling in bronchial asthma rats; using the RT-PCR and Western-blot methods to assess the expressions of Caspase-3, Bax and Bcl-2 of lung tissue in bronchial asthma rats. Results: Compared with the bronchial asthma model group, the GA (200mg/kg) could amelio- rate the asthma rat's airway inflammation and remodeling; the GA (200, 100mg/kg) could up-regulate the bronchial asthma rat's lung tissue mRNA and protein expression levels of Caspase-3 and Bax, and down-regulate the Bcl-2 expression level. Conclusion: GA could ameliorate the asthma rat's airway inflammation and remodeling, and its mechanism was related to up-regulate the Caspase-3 and Bax, and down-regulate the Bcl-2.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.118.193.52